Neurology Today

Consortium of Multiple Sclerosis Centers Annual Meeting

Neurology Today is offering a new e-news service — the Neurology Today Conference Reporter — to keep neurologists up to date and fully informed about the most noteworthy news from major professional meetings.  

Whether you are attending the meeting or reading about it remotely, you’ll be able to access daily, concise peer-reviewed reports from major neurology conferences via email blasts that are optimized for web and mobile viewing.

The Neurology Today Conference Reporter will highlight only those papers and presentations deemed noteworthy by the Neurology Today editors. All reports will be vetted and reviewed by our team of neurologist reviewers, as well. Each report will include commentary from independent experts and will appear with additional perspectives in the print edition of Neurology Today.

 

Hot off the press from the Consortium of Multiple Sclerosis Centers Annual Meeting: 

 

May 30—Post-Hoc Analysis: Benefits of Interferon Beta-1A Found in Patients with More Advanced MS

Read expanded coverage here.

 

May 30—Lymphopenia Associated with Dimethyl Fumarate Disproportionately Lowers CD8+ Cells

Read expanded coverage here.

 

May 30—Benefits of Alemtuzumab Seen Whether Switching from Fingolimod, Natalizumab, or Glatiramer Acetate

 

May 29—Benefits of Alemtuzumab on MRI Activity and Brain Atrophy Seen to Persist for Four Years

 

May 29—Patient-Centered Functional Outcomes Improve More on Daclizumab than on Interferon Beta-1A: New Data from DECIDE

Read expanded coverage here.

 

May 29—BMI Linked to Risk of MS Progression in Observational Study

Read expanded coverage here.

CMSC Annual Meeting Blog
Fay.Ellis
Access daily, concise peer-reviewed reports from the CMSC Annual Meeting selected by the Neurology Today editors.

Latest Entry: 5/30/2015 May 30—Benefits of Alemtuzumab Seen Whether Switching from Fingolimod, Natalizumab, or Glatiramer Acetate